Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women

Authors: Abrha G. Gebrehiwot, Daniel Seifu Melka, Yimenashu Mamo Kassaye, Tufa Gemechu, Wajana Lako, Hiroshi Hinou, Shin-Ichiro Nishimura

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Alterations in protein glycosylation patterns have potentially been targeted for biomarker discovery in a wide range of diseases including cancer. Although there have been improvements in patient diagnosis and survival for breast cancer (BC), there is no clinically validated serum biomarker for its early diagnosis. Here, we profiled whole serum and purified Immunoglobulin G (IgG) fraction N-glycome towards identification of non-invasive glycan markers of BC.

Methods

We employed a comprehensive glycomics approach by integrating glycoblotting-based glycan purification with MALDI-TOF/MS based quantitative analysis. Sera of BC patients belonging to stages I-IV and normal controls (NC) were collected from Ethiopian women during 2015–2016. IgG was purified by affinity chromatography using protein G spin plate and further subjected to glycoblotting for glycan release. Mass spectral data were further processed and evaluated rigorously, using various bioinformatics and statistical tools.

Results

Out of 35 N-glycans that were significantly up-regulated in the sera of all BC patients compared to the NC, 17 complex type N-glycans showed profound expression abundance and diagnostic potential (AUC = 0.8–1) for the early stage (I and II) BC patients. Most of these glycans were core-fucosylated, multiply branched and sialylated structures, whose abundance has been strongly associated with greater invasive and metastatic potential of cancer. N-glycans quantified form IgG confirmed their abundance in BC patients, of which two core-fucosylated and agalactosylated glycans (m/z 1591, 1794) could specifically distinguish (AUC = 0.944 and 0.921, p ≤ 0.001) stage II patients from NC. Abundance of such structural features in IgG is associated with a decrease in its immunosuppressive potential towards tumor cells, which in part may correlate with the aggressive nature of BC commonly noticed in black population.

Conclusions

Our comprehensive study has addressed for the first time both whole serum and IgG N-glycosylation signatures of native black women suffering from BC and revealed novel glyco-biomarkers with marked overexpression and distinguishing ability at early stage patients. Further studies on direct identification of the intact glycoproteins using a glycoprteomics approach will provide a deeper understanding of specific biomarkers towards their clinical utility.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRef Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRef
2.
go back to reference American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc; 2017. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc; 2017.
3.
go back to reference Xin J, Ping M. Targeting breast Cancer metastasis. Breast Cancer (Auckl). 2015;9:23–34. Xin J, Ping M. Targeting breast Cancer metastasis. Breast Cancer (Auckl). 2015;9:23–34.
6.
go back to reference Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.CrossRef Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.CrossRef
7.
go back to reference Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473–510.CrossRef Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473–510.CrossRef
8.
go back to reference Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016;33:309–43.CrossRef Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016;33:309–43.CrossRef
9.
go back to reference Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.CrossRef Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.CrossRef
10.
go back to reference Pinho SS, Carvalho S, Marcos-Pinto R, et al. Gastric cancer: adding glycosylation to the equation. Trends Mol Med. 2013;19:664–76.CrossRef Pinho SS, Carvalho S, Marcos-Pinto R, et al. Gastric cancer: adding glycosylation to the equation. Trends Mol Med. 2013;19:664–76.CrossRef
11.
go back to reference Christopher AC, Stefani NT, Lori JS, Daniel WC. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 2016;13:1.CrossRef Christopher AC, Stefani NT, Lori JS, Daniel WC. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 2016;13:1.CrossRef
12.
go back to reference An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, Leiserowitz GS, Lebrilla CB. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5:1626–35.CrossRef An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, Leiserowitz GS, Lebrilla CB. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5:1626–35.CrossRef
13.
go back to reference Snyder CM, Alley WR Jr, Campos MI, Svoboda M, Goetz JA, Vasseur JA, Jacobson SC, Novotny MV. Complementary Glycomic analyses of sera derived from colorectal Cancer patients by MALDI-TOF-MS and microchip electrophoresis. Anal Chem. 2016;88:9597–605.CrossRef Snyder CM, Alley WR Jr, Campos MI, Svoboda M, Goetz JA, Vasseur JA, Jacobson SC, Novotny MV. Complementary Glycomic analyses of sera derived from colorectal Cancer patients by MALDI-TOF-MS and microchip electrophoresis. Anal Chem. 2016;88:9597–605.CrossRef
14.
go back to reference Sethi MK, Hancock WS, Fanayan S. Identifying N-glycan biomarkers in colorectal Cancer by mass spectrometry. Acc Chem Res. 2016;49:2099–106.CrossRef Sethi MK, Hancock WS, Fanayan S. Identifying N-glycan biomarkers in colorectal Cancer by mass spectrometry. Acc Chem Res. 2016;49:2099–106.CrossRef
15.
go back to reference Qin R, Zhao J, Qin W, et al. Discovery of non-invasive glycan biomarkers for detection and surveillance of gastric Cancer. J Cancer. 2017;8:1908–16.CrossRef Qin R, Zhao J, Qin W, et al. Discovery of non-invasive glycan biomarkers for detection and surveillance of gastric Cancer. J Cancer. 2017;8:1908–16.CrossRef
16.
go back to reference Nouso K, Amano M, Ito YM, et al. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol. 2013;48:1171–9.CrossRef Nouso K, Amano M, Ito YM, et al. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol. 2013;48:1171–9.CrossRef
17.
go back to reference Ishibashi Y, Tobisawa Y, Hatakeyama S, Ohashi T, Tanaka M, Narita S, Koie T, Habuchi T, Nishimura S, Ohyama C, Yoneyama T. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer. Prostate. 2014;74:1521–9.CrossRef Ishibashi Y, Tobisawa Y, Hatakeyama S, Ohashi T, Tanaka M, Narita S, Koie T, Habuchi T, Nishimura S, Ohyama C, Yoneyama T. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer. Prostate. 2014;74:1521–9.CrossRef
18.
go back to reference Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, Nakanishi K, Kamachi H, Kakisaka T, Tsuruga Y, Fujiyoshi M, Taketomi A, Nishimura S, Todo S. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology. 2013;57:2314–25.CrossRef Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, Nakanishi K, Kamachi H, Kakisaka T, Tsuruga Y, Fujiyoshi M, Taketomi A, Nishimura S, Todo S. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology. 2013;57:2314–25.CrossRef
19.
go back to reference Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV. Breast Cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008;54:1166–75.CrossRef Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV. Breast Cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008;54:1166–75.CrossRef
20.
go back to reference Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale A-L, Yakhini Z. Serum N-glycan analysis in breast cancer patients – relation to tumour biology and clinical outcome. Mol Oncol. 2016;10:59–72.CrossRef Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale A-L, Yakhini Z. Serum N-glycan analysis in breast cancer patients – relation to tumour biology and clinical outcome. Mol Oncol. 2016;10:59–72.CrossRef
21.
go back to reference De Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, Borowsky AD, Chew HK, Lebrilla CB. High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics. 2011;10:M110.002717.CrossRef De Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, Borowsky AD, Chew HK, Lebrilla CB. High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics. 2011;10:M110.002717.CrossRef
22.
go back to reference Goetz JA, Mechref Y, Kang P, Novotny MV. Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J. 2009;26:117–31.CrossRef Goetz JA, Mechref Y, Kang P, Novotny MV. Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J. 2009;26:117–31.CrossRef
23.
go back to reference Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, Ferrige A, Alecio R, Borowsky AD, Sulaimon S, Lebrilla CB, Miyamoto SA. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 2007;6:43–55.CrossRef Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, Ferrige A, Alecio R, Borowsky AD, Sulaimon S, Lebrilla CB, Miyamoto SA. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 2007;6:43–55.CrossRef
24.
go back to reference Lee LY, Thaysen-Andersen M, Baker MS, Packer NH, Hancock WS, Fanayan S. Comprehensive N-Glycome profiling of cultured human epithelial breast cells identifies unique Secretome N-glycosylation signatures enabling tumorigenic subtype classification. J Proteome Res. 2014;13:4783–95.CrossRef Lee LY, Thaysen-Andersen M, Baker MS, Packer NH, Hancock WS, Fanayan S. Comprehensive N-Glycome profiling of cultured human epithelial breast cells identifies unique Secretome N-glycosylation signatures enabling tumorigenic subtype classification. J Proteome Res. 2014;13:4783–95.CrossRef
25.
go back to reference Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M. Serum immunoglobulin G fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochem Biophys Res Commun. 2016;469:1140–5.CrossRef Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M. Serum immunoglobulin G fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochem Biophys Res Commun. 2016;469:1140–5.CrossRef
26.
go back to reference Vučković F, Theodoratou E, Thaçi K, et al. IgG Glycome in colorectal Cancer. Clin Cancer Res. 2016;22:3078–86.CrossRef Vučković F, Theodoratou E, Thaçi K, et al. IgG Glycome in colorectal Cancer. Clin Cancer Res. 2016;22:3078–86.CrossRef
27.
go back to reference Kodar K, Stadlmann J, Klaamas K, et al. Immunoglobulin G fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J. 2012;29:57–66.CrossRef Kodar K, Stadlmann J, Klaamas K, et al. Immunoglobulin G fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J. 2012;29:57–66.CrossRef
28.
go back to reference Nishimura S-I. Toward automated glycan analysis. Adv Carbohydr Chem Biochem. 2011;65:219–71.CrossRef Nishimura S-I. Toward automated glycan analysis. Adv Carbohydr Chem Biochem. 2011;65:219–71.CrossRef
29.
go back to reference Hatakeyama S, Amano M, Tobisawa Y, et al. Serum N-glycan alteration associated with renal cell carcinoma detected by high-throughput glycan analysis. J Urol. 2014;191:805–13.CrossRef Hatakeyama S, Amano M, Tobisawa Y, et al. Serum N-glycan alteration associated with renal cell carcinoma detected by high-throughput glycan analysis. J Urol. 2014;191:805–13.CrossRef
30.
go back to reference Gizaw ST, Koda T, Amano M, Kamimura K, Ohashi T, Hinou H, Nishimura S-I. A comprehensive glycome profiling of Huntington's disease transgenic mice. BBA-Gen Subjects. 2015;1850:1704–18.CrossRef Gizaw ST, Koda T, Amano M, Kamimura K, Ohashi T, Hinou H, Nishimura S-I. A comprehensive glycome profiling of Huntington's disease transgenic mice. BBA-Gen Subjects. 2015;1850:1704–18.CrossRef
31.
go back to reference Gizaw ST, Ohashi T, Tanaka M, Hinou H, Nishimura S-I. Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer’s disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. BBA-Gen Subjects. 2016;1860:1716–27.CrossRef Gizaw ST, Ohashi T, Tanaka M, Hinou H, Nishimura S-I. Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer’s disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. BBA-Gen Subjects. 2016;1860:1716–27.CrossRef
32.
go back to reference Inafuku S, Noda K, Amano M, Ohashi T, Yoshizawa C, Saito W, Murata M, Kanda A, Nishimura S-I, Ishida S. Alteration of N-glycan profiles in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2015;56:5316–22.CrossRef Inafuku S, Noda K, Amano M, Ohashi T, Yoshizawa C, Saito W, Murata M, Kanda A, Nishimura S-I, Ishida S. Alteration of N-glycan profiles in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2015;56:5316–22.CrossRef
33.
go back to reference Hatakeyama S, Amano M, Tobisawa Y, Yoneyama T, Tsushima M, Hirose K, Yoneyama T, Hashimoto Y, Koie T, Saitoh H, Yamaya K, Funyu T, Nisimura S-I, Ohyama C. Serum N-glycan profiling predicts prognosis in patients undergoing hemodialysis. Sci World J. 2013;2013:268407. Hatakeyama S, Amano M, Tobisawa Y, Yoneyama T, Tsushima M, Hirose K, Yoneyama T, Hashimoto Y, Koie T, Saitoh H, Yamaya K, Funyu T, Nisimura S-I, Ohyama C. Serum N-glycan profiling predicts prognosis in patients undergoing hemodialysis. Sci World J. 2013;2013:268407.
34.
go back to reference Urita A, Matsuhashi T, Onodera T, Nakagawa H, Hato M, Amano M, Seito N, Minami A, Nishimura S, Iwasaki N. Alterations of High-mannose Type N-Glycosylation in Human and Mouse Ostesarthritis Cartilage. Arthritis Rheum. 2011;63:3428–38.CrossRef Urita A, Matsuhashi T, Onodera T, Nakagawa H, Hato M, Amano M, Seito N, Minami A, Nishimura S, Iwasaki N. Alterations of High-mannose Type N-Glycosylation in Human and Mouse Ostesarthritis Cartilage. Arthritis Rheum. 2011;63:3428–38.CrossRef
35.
go back to reference Kita Y, Miura Y, Furukawa J, Nakano M, Shinohara Y, Ohno M, Takimoto A, Nishimura S-I. Quantitative glycomics of human whole serum glycoprotein based on the standardized protocol for liberating N-glycans. Mol Cell Proteomics. 2007;6:1437–45.CrossRef Kita Y, Miura Y, Furukawa J, Nakano M, Shinohara Y, Ohno M, Takimoto A, Nishimura S-I. Quantitative glycomics of human whole serum glycoprotein based on the standardized protocol for liberating N-glycans. Mol Cell Proteomics. 2007;6:1437–45.CrossRef
36.
go back to reference Furukawa J, Shinohara Y, Kuramoto H, Miura Y, Shimaoka H, Kurogochi M, Nakano M, Nishimura S-I. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal Chem. 2008;80:1094–101.CrossRef Furukawa J, Shinohara Y, Kuramoto H, Miura Y, Shimaoka H, Kurogochi M, Nakano M, Nishimura S-I. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal Chem. 2008;80:1094–101.CrossRef
37.
go back to reference Nishimura S-I, Niikura K, Kurogochi M, Matsushita T, Fumoto M, Hinou H, Kamitani M, Nakagawa H, Deguchi K, Miura M, Monde K, Kondo H. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectroscopy. Angew Chem Int Ed. 2004;44:91–6.CrossRef Nishimura S-I, Niikura K, Kurogochi M, Matsushita T, Fumoto M, Hinou H, Kamitani M, Nakagawa H, Deguchi K, Miura M, Monde K, Kondo H. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectroscopy. Angew Chem Int Ed. 2004;44:91–6.CrossRef
38.
go back to reference Pearce OM, Läubli H. Sialic acids in cancer biology and immunity. Glycobiology. 2016;26:111–28.CrossRef Pearce OM, Läubli H. Sialic acids in cancer biology and immunity. Glycobiology. 2016;26:111–28.CrossRef
39.
go back to reference Tu C-F, Wu M-Y, Lin Y-C, Kannagi R, Yang R-B. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. Breast Cancer Res. 2017;19:111.CrossRef Tu C-F, Wu M-Y, Lin Y-C, Kannagi R, Yang R-B. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. Breast Cancer Res. 2017;19:111.CrossRef
40.
go back to reference Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res. 2005;11:2969–73.CrossRef Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res. 2005;11:2969–73.CrossRef
41.
go back to reference Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 1998;58:4066–70.PubMed Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 1998;58:4066–70.PubMed
42.
go back to reference Cui H, Lin Y, Yue L, Zhao X, Liu J. Differential expression of the alpha 2,3-sialic acid residues in breast cancer is associated with metastatic potential. Oncol Rep. 2011;25:1365–71.PubMed Cui H, Lin Y, Yue L, Zhao X, Liu J. Differential expression of the alpha 2,3-sialic acid residues in breast cancer is associated with metastatic potential. Oncol Rep. 2011;25:1365–71.PubMed
43.
go back to reference Zhao Y, Nakagawa T, Itoh S, et al. N-Acetylglucosaminyltransferase III antagonizes the effect of N-Acetylglucosaminyltransferase V on α3β1 integrin-mediated cell migration. J Biol Chem. 2006;281:32122–30.CrossRef Zhao Y, Nakagawa T, Itoh S, et al. N-Acetylglucosaminyltransferase III antagonizes the effect of N-Acetylglucosaminyltransferase V on α3β1 integrin-mediated cell migration. J Biol Chem. 2006;281:32122–30.CrossRef
44.
go back to reference Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology. 2002;12:119–27.CrossRef Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology. 2002;12:119–27.CrossRef
45.
go back to reference Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.CrossRef Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.CrossRef
46.
go back to reference Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: the human N-glycome. BBA-Gen subjects. 2016;1860:1574–82.CrossRef Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: the human N-glycome. BBA-Gen subjects. 2016;1860:1574–82.CrossRef
47.
go back to reference Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang L-X. Modulating IgG effector function by fc glycan engineering. Proc Natl Acad Sci. 2017;114:3485–90.CrossRef Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang L-X. Modulating IgG effector function by fc glycan engineering. Proc Natl Acad Sci. 2017;114:3485–90.CrossRef
48.
go back to reference Peschke B, Keller CW, Weber P, Quast I, Lünemann JD. Fc Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol. 2017;8:646.CrossRef Peschke B, Keller CW, Weber P, Quast I, Lünemann JD. Fc Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol. 2017;8:646.CrossRef
49.
go back to reference Li W, Zhu Z, Chen W, Feng Y, Dimitrov DS. Crystallizable fragment Glycoengineering for therapeutic antibodies development. Front Immunol. 2017;8:1554.CrossRef Li W, Zhu Z, Chen W, Feng Y, Dimitrov DS. Crystallizable fragment Glycoengineering for therapeutic antibodies development. Front Immunol. 2017;8:1554.CrossRef
50.
go back to reference Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornic O, Supraha-Goreta S, Wormald MR, Redzic I, Campbell H, Wright A, Hastie ND, Wilson JF, Rudan I, Wuhrer M, Rudd PM, Josic D, Lauc G. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011;10:M111.010090.CrossRef Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornic O, Supraha-Goreta S, Wormald MR, Redzic I, Campbell H, Wright A, Hastie ND, Wilson JF, Rudan I, Wuhrer M, Rudd PM, Josic D, Lauc G. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011;10:M111.010090.CrossRef
51.
go back to reference Terashima M, Amano M, Onodera T, Shin-Ichiro Nishimura S-I, Iwasaki N. Quantitative glycomics monitoring of induced pluripotent- and embryonic stem cells during neuronal differentiation. Stem Cell Res. 2014;13:454–64.CrossRef Terashima M, Amano M, Onodera T, Shin-Ichiro Nishimura S-I, Iwasaki N. Quantitative glycomics monitoring of induced pluripotent- and embryonic stem cells during neuronal differentiation. Stem Cell Res. 2014;13:454–64.CrossRef
52.
go back to reference DeSantis CE, Fedewa SA, Goding SA, Kramer JL, Smith RA, Jemal A. Breast Cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31–42.CrossRef DeSantis CE, Fedewa SA, Goding SA, Kramer JL, Smith RA, Jemal A. Breast Cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31–42.CrossRef
53.
go back to reference Swanson GM, Haslam SZ, Azzouz F. Breast Cancer among Young African-American women. Cancer. 2002;97:273–9.CrossRef Swanson GM, Haslam SZ, Azzouz F. Breast Cancer among Young African-American women. Cancer. 2002;97:273–9.CrossRef
54.
go back to reference Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2–8.PubMedPubMedCentral Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2–8.PubMedPubMedCentral
55.
go back to reference Morris GY, Mitchell EP. Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc. 2008;100:698–702.CrossRef Morris GY, Mitchell EP. Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc. 2008;100:698–702.CrossRef
56.
go back to reference Almeida A, Kolarich D. The promise of protein glycosylation for personalised medicine. BBA-Gen Subject. 2016;1860:1583–95.CrossRef Almeida A, Kolarich D. The promise of protein glycosylation for personalised medicine. BBA-Gen Subject. 2016;1860:1583–95.CrossRef
Metadata
Title
Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women
Authors
Abrha G. Gebrehiwot
Daniel Seifu Melka
Yimenashu Mamo Kassaye
Tufa Gemechu
Wajana Lako
Hiroshi Hinou
Shin-Ichiro Nishimura
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5817-8

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine